Skip to main content
Caplight Logo









Fasikl, Inc.

Fasikl, Inc.

Private
Minneapolis, MinnesotaHealthcare & Life Scienceshttps://www.fasikl.com/

Last Round

Series B

Sep 10, 2025

Total Funding Raised

$59.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Fasikl, Inc. is a neuro-AI company that develops cloud-connected, AI-powered neuromodulation technologies and therapeutics for movement disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Biotechnology

Business Model

B2B2C

Customer Profile

Hardware Sales, Usage-Based SaaS

AI Layer

Application

Keywords

neuromodulationessential tremor treatmentmedical deviceAI therapeuticdigital therapeuticsnon-invasive neuromodulationclosed-loop neuromodulationFDA-cleared deviceneurotechwearable medical devicemovement disorder treatmentadaptive stimulationhealth IoTbioelectronic medicineneural decoding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fasikl, Inc. Comparables

Compare Fasikl, Inc. with similar companies based on industry and business-model similarity.

Fasikl, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Encora Therapeutics
87%
Allevion Therapeutics
85%
Cala Health
85%

Fasikl, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 10, 2025
Series A ExtensionSep 10, 2024
Series AMar 3, 2023
SeedNov 1, 2021

Key People

Founding team and executive leadership

Edward W. Keefer

Co-Founder and Chief Scientific Officer

Founding Team

Zhi Yang

CEO

Executive Team

Catherine Zhao

Chief Technology Officer

Executive Team

Fasikl, Inc. Investors

Notable investors and investment history

Fasikl, Inc. investors
InvestorRounds
iSeedSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 122% MoM, reaching 4.1K.

  • May 2, 2026

    Flagship non-invasive neuromodulation solution for essential tremor is FDA-cleared.

Fasikl, Inc. Filings

Explore SEC and related filing metadata, where available.

Fasikl, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Fasikl, Inc.'s valuation, stock price, and market status.

Is Fasikl, Inc. a public or private company?

Fasikl, Inc. is a private company.

What is the current stock price of Fasikl, Inc.?

Fasikl, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Fasikl, Inc. worth (valuation)?

Valuation information for Fasikl, Inc. is not publicly available.

Can I buy Fasikl, Inc. stock?

Fasikl, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Fasikl, Inc.'s last funding round?

Fasikl, Inc.'s most recent funding round was Series B on September 10, 2025.

Who are the main investors in Fasikl, Inc.?

Key investors in Fasikl, Inc. include iSeed.

Will Fasikl, Inc. IPO soon?

No public IPO plans have been announced for Fasikl, Inc..

How can I track Fasikl, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Fasikl, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMinneapolis, Minnesota
Employee Range13
Year Founded2019
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?